Analyst: Rival woes is positive news for Bavarian
An analyst from Nordic Bioinvestor sees it as a positive thing for Bavarian Nordic, should a major US rival buckle under recent financial pressure. The analyst is bullish on the share, not least due to the company’s infectious diseases division.
by Henrik Tüchsen
If the US-based company Dendreon, maker of prostate cancer drug Provenge, were to buckle under recent pressure, it would seemingly be to the advantage of Bavarian Nordic – a Denmark-based rival on the prostate cancer market. But the bright prospects for the Danish company are mainly due to its other division for vaccines against infectious diseases.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian CEO switches to GN Resound
For abonnenter
Does Bavarian have a blockbuster in the making?
For abonnenter
Bavarian looking for partnerships for cancer vaccine
For abonnenter
